WebDoctor Encyclopedia

Central nervous system Childhood

Embryonal tumour with multilayered rosettes (ETMR)

Embryonal tumour with multilayered rosettes (ETMR) is a rare, fast-growing grade 4 brain tumour of infants and young children, defined by C19MC or DICER1 changes. It is treated with surgery, high-dose chemotherapy with stem cell rescue and radiotherapy.

Medically reviewed Last reviewed October 19, 2026

What is an embryonal tumour with multilayered rosettes?

An embryonal tumour with multilayered rosettes, or ETMR, is a rare and fast-growing brain tumour of very young children. Most children are diagnosed before their fourth birthday, often around the age of two.

“Embryonal” means the tumour is made of immature cells that look like the early cells of a developing brain. “Multilayered rosettes” describes a ring-like pattern of tumour cells, several layers thick, that pathologists see under the microscope.

ETMR is classed as a CNS WHO grade 4 tumour, the most aggressive category. It grows quickly and is difficult to treat. In the past it was known by several different names, including ETANTR, ependymoblastoma and medulloepithelioma, before research showed that these were the same disease.

Almost all ETMRs share one key genetic change: extra copies or rearrangement of a cluster of microRNA genes on chromosome 19, called C19MC. Finding this change, or the related protein LIN28A, confirms the diagnosis (Lambo et al., 2019).

Treatment combines surgery, intensive chemotherapy with stem cell rescue and radiotherapy. Outcomes are still poor for many children, but a growing number survive with this intensive approach (Khan et al., 2021).

1. Key facts at a glance

Feature Details
Type of tumour Embryonal (immature cell) brain tumour
WHO grade CNS WHO grade 4
How common Very rare; a small fraction of childhood brain tumours
Typical age Infants and young children; median age a little over 2 years
Sex Roughly equal; some series show slightly more girls
Usual sites Cerebral hemispheres in about half; brainstem, cerebellum and other sites in the rest
Key gene change C19MC amplification or fusion in about 9 in 10; DICER1 changes in some others
Main treatment Surgery, high-dose chemotherapy with stem cell rescue, radiotherapy
Outlook Serious; long-term survival in a minority, better with complete removal and radiotherapy

2. Causes and risk factors

The cause of ETMR is not known. Parents should know that nothing they did or did not do during pregnancy or early childhood caused the tumour.

Gene changes

Gene change Notes
C19MC amplification Extra copies of a microRNA cluster on chromosome 19; often fused with the TTYH1 gene
LIN28A A protein strongly switched on in the tumour; used as a diagnostic stain
DICER1 changes Found in most ETMRs without C19MC change; occasionally inherited
Chromosome 2 gain Common additional change

Inherited risk

Most ETMRs are not inherited. A small number of children without the C19MC change carry an inherited DICER1 variant, which also raises the risk of other rare tumours (Lambo et al., 2019). Genetic counselling may be offered to the family in this situation.

3. How does it look

On scans

Feature Description
Size Often large at diagnosis, sometimes several centimetres across
Position Cerebral hemisphere, brainstem, cerebellum or elsewhere
Edges Usually well defined, with little swelling around it
Signal Solid areas, sometimes with cysts, calcification or bleeding
Contrast enhancement Often patchy or weak, despite the tumour’s aggressiveness
Spread Spine MRI may show seeding along the spinal fluid spaces

During surgery

The tumour is often soft, greyish and fairly well circumscribed, which can allow surgeons to remove it completely when it lies in a cerebral hemisphere. Tumours in the brainstem are much harder to remove safely.

Under the microscope

Feature Description
Cells Small, round, immature cells with scant cytoplasm and many mitoses
Rosettes Multilayered ring-shaped structures around a central space
Neuropil Pale, fibrillary areas resembling immature nerve tissue
LIN28A stain Strongly positive in tumour cells
Molecular tests FISH or methylation profiling to detect C19MC alteration

4. Symptoms

Symptoms usually develop quickly, over days to weeks, because the tumour grows fast. Young children cannot describe how they feel, so the signs are often changes in behaviour, feeding or development.

Signs of raised pressure in the head

  • Vomiting, especially in the morning
  • Irritability or unusual crying
  • Sleepiness or lack of energy
  • Headache in children old enough to describe it
  • An enlarging head in babies, with a bulging soft spot (fontanelle)
  • Eyes that look downwards (“sunsetting”) in infants

Symptoms depending on the site

Site Possible symptoms
Cerebral hemisphere Seizures, weakness on one side, loss of skills
Brainstem Squint or double vision, facial weakness, swallowing difficulty, unsteadiness
Cerebellum Wobbly walking, poor balance and coordination
Spine (if spread) Back pain, weakness of the legs

Developmental signs

Sign What to watch for
Loss of skills A child stops sitting, walking or talking as before
Delayed milestones Not reaching expected skills
Head tilt Holding the head to one side

When to seek medical advice

See a doctor promptly if a young child has repeated vomiting, unusual sleepiness, a rapidly growing head, a seizure, or loses skills they had already learned. Seek emergency care if a child is very drowsy, difficult to wake or has a prolonged seizure.

5. Diagnosis

Test Purpose
Neurological examination Checks movement, balance, eye movements and development
CT scan Rapid first test in an emergency
MRI of the brain and spine Shows the tumour in detail and checks for spread
Lumbar puncture Looks for tumour cells in spinal fluid, usually after surgery
Surgery and pathology Confirms the diagnosis
LIN28A and molecular testing Confirms ETMR and separates it from other embryonal tumours
Hearing and kidney tests Baselines before chemotherapy

Other tumours that can look similar

ETMR can be confused with medulloblastoma, atypical teratoid/rhabdoid tumour (AT/RT), ependymoma and other CNS embryonal tumours. Modern tests such as DNA methylation profiling have made these distinctions much more reliable (Liu et al., 2022).

6. Treatment

Treatment takes place in a specialist children’s cancer centre and is planned by a team including paediatric neurosurgeons, oncologists, radiation oncologists and nurses.

Surgery

The first step is usually an operation to remove as much of the tumour as safely possible. If there is a build-up of fluid, a temporary drain or a permanent shunt may be needed. Complete removal (gross total resection) is one of the strongest factors linked with survival (Khan et al., 2021).

Chemotherapy

Phase Notes
Induction Several cycles of combination chemotherapy to shrink remaining tumour
High-dose chemotherapy Very strong chemotherapy followed by return of the child’s own stored stem cells
Drugs given into the spinal fluid Used in some protocols

Radiotherapy

Option Notes
Focal radiotherapy Treats the tumour area; proton therapy may reduce harm to the developing brain
Craniospinal radiotherapy Treats the whole brain and spine when there is spread
Timing Often delayed or carefully planned in very young children because of late effects

In a large international registry, children who received high-dose chemotherapy and radiotherapy had the best results, and those treated with standard chemotherapy without radiotherapy did very poorly (Khan et al., 2021). A registry of children treated with proton radiotherapy reported good local control at 4 years (Krisch et al., 2025).

Why ETMR is difficult to treat

  • It grows quickly, so children are often unwell by the time it is found
  • Many tumours arise in the brainstem, where complete removal is rarely possible
  • Children are very young, which limits the safe dose of radiotherapy
  • The tumour often comes back early, usually within the first year, if treatment is not intensive
  • Because it is so rare, few clinical trials have been designed specifically for ETMR

Researchers are testing new approaches, including drugs aimed at the pathways switched on by C19MC and LIN28A. Laboratory studies of tumours at relapse also show how the cancer changes over time, which may guide future treatment (Lambo et al., 2019).

Side effects and late effects

Treatment Possible effects
Surgery Bleeding, infection, weakness, speech or swallowing problems
High-dose chemotherapy Very low blood counts, infections, mouth sores, hearing loss, kidney effects
Radiotherapy Tiredness, hair loss; later effects on learning, growth and hormones
Long term Learning difficulties, hearing loss, short stature, risk of second tumours

What treatment involves day to day

Part of treatment What to expect
After surgery Several days in intensive care or a neurosurgical ward
Chemotherapy Many hospital stays over several months
Stem cell rescue Weeks in hospital while blood counts recover
Radiotherapy Daily sessions, often under general anaesthetic for young children

7. Outlook (prognosis)

Situation Approximate outlook
All children treated with curative intent About 3 in 10 alive at 2 years in a large registry
Complete removal, high-dose chemotherapy and radiotherapy Best results; about 2 in 3 event-free at 2 years in one group
Conventional chemotherapy without radiotherapy Very poor
Brainstem tumours or spread at diagnosis Worse outlook

These figures come from the Rare Brain Tumor Consortium, which studied 159 children with confirmed ETMR (Khan et al., 2021). In that study, survival changed little between 2 and 4 years, which suggests that children who stay free of tumour for the first couple of years have a much better chance of long-term survival. Numbers vary between studies and every child is different. The care team can explain what the figures mean for your child.

8. Follow-up

Follow-up Purpose
MRI of brain and spine Every 2-3 months at first, then less often
Hearing tests Check for hearing loss from chemotherapy
Growth and hormone checks Especially after radiotherapy
Developmental and learning assessments Plan support at nursery and school
Long-term survivorship clinic Monitors late effects into adulthood

9. Living with ETMR

  • Ask for a key worker or specialist nurse to help coordinate care between the different teams
  • Learn the signs of infection during chemotherapy and when to call the hospital
  • Keep a folder of test results, treatment plans and contact numbers
  • Ask about physiotherapy, speech therapy and occupational therapy for recovery
  • Look after siblings and yourselves; social workers and psychologists can help the whole family
  • Seek support from childhood cancer charities and parent groups
  • Discuss palliative care early if treatment is not working; it focuses on comfort and can be given alongside other treatment

10. Frequently asked questions

Question Answer
Did we cause this? No. Nothing parents do causes ETMR
Is it inherited? Usually not; a few children have an inherited DICER1 change
Can it be cured? Some children survive long term with intensive treatment
Why is radiotherapy used in young children? It improves survival in ETMR, although it carries risks for the developing brain
What is stem cell rescue? The child’s own blood stem cells are collected and returned after very high-dose chemotherapy
Are there clinical trials? Yes, in some countries; ask the team

11. Questions to ask your care team

  • Has the diagnosis been confirmed with LIN28A or C19MC testing?
  • Was the tumour completely removed? Would further surgery help?
  • Has it spread to the spine or spinal fluid?
  • What does the treatment plan involve, and for how long?
  • Is proton therapy an option?
  • What late effects should we watch for, and what support is available?

Resources

  1. Khan, S. et al. (2021) ‘Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study’, Lancet Child and Adolescent Health, 5(11), pp. 800-813.
  2. Krisch, J.M. et al. (2025) ‘Outcomes following radiation therapy for embryonal tumor with multilayered rosettes (ETMR): results from the Pediatric Proton/Photon Consortium Registry (PPCR)’, Journal of Neuro-Oncology, 174(2), pp. 369-380.
  3. Lambo, S. et al. (2019) ‘The molecular landscape of ETMR at diagnosis and relapse’, Nature, 576(7786), pp. 274-280.
  4. Liu, A.P.Y. et al. (2022) ‘Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children’s Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials’, Acta Neuropathologica, 144(4), pp. 733-746.
  5. Pei, Y.C. et al. (2019) ‘Embryonal tumor with multilayered rosettes, C19MC-altered (ETMR): a newly defined pediatric brain tumor’, International Journal of Clinical and Experimental Pathology, 12(8), pp. 3156-3163.
  6. Xu, K. et al. (2022) ‘Embryonal tumors with multilayered rosettes, C19MC-altered or not elsewhere classified: clinicopathological characteristics, prognostic factors, and outcomes of 17 children from 2018 to 2022’, Frontiers in Oncology, 12, 1001959.
  7. National Cancer Institute (2026) Childhood Central Nervous System Embryonal Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.